ATXN9 (Ataxin-9) is a protein-coding gene located on chromosome 3p21.1 that has garnered significant attention in neurodegeneration research due to its associations with multiple neurodegenerative diseases, including Spinocerebellar Ataxia Type 17 (SCA17), Alzheimer's disease, Parkinson's disease, and Huntington's disease[^ncbi][^omim]. The gene encodes a protein belonging to the Ataxin family, characterized by polyglutamine (polyQ) tracts in their N-terminal regions. Although originally thought to cause SCA17, subsequent research identified TBP (TATA-binding protein) as the actual causative gene, yet ATXN9 remains of considerable interest due to its broader implications in neurodegeneration and protein quality control pathways[^genecards].
ATXN9 (Ataxin-9) is a protein-coding gene located on chromosome 3p21.1 that has garnered significant attention in neurodegeneration research due to its associations with multiple neurodegenerative diseases, including Spinocerebellar Ataxia Type 17 (SCA17), Alzheimer's disease, Parkinson's disease, and Huntington's disease[^ncbi][^omim]. The gene encodes a protein belonging to the Ataxin family, characterized by polyglutamine (polyQ) tracts in their N-terminal regions. Although originally thought to cause SCA17, subsequent research identified TBP (TATA-binding protein) as the actual causative gene, yet ATXN9 remains of considerable interest due to its broader implications in neurodegeneration and protein quality control pathways[^genecards].
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background-color: #4a90d9; color: white; text-align: center;">ATXN9</th></tr>
<tr><td colspan="2" style="text-align: center; padding: 10px;"><b>Ataxin-9</b></td></tr>
<tr><th style="width: 40%;">Symbol</th><td>ATXN9</td></tr>
<tr><th>Chromosome</th><td>3p21.1</td></tr>
<tr><th>NCBI Gene ID</th><td><a href="https://www.ncbi.nlm.nih.gov/gene/ATXN9" target="_blank">ATXN9</a></td></tr>
<tr><th>OMIM</th><td><a href="https://www.omim.org/entry/608306" target="_blank">608306</a></td></tr>
<tr><th>Ensembl ID</th><td><a href="https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000125885" target="_blank">ENSG00000125885</a></td></tr>
<tr><th>UniProt</th><td><a href="https://www.uniprot.org/uniprot/Q9BQN5" target="_blank">Q9BQN5</a></td></tr>
<tr><th>Associated Diseases</th><td>Spinocerebellar Ataxia Type 17 (SCA17)</td></tr>
</table>
</div>
ATXN9 (Ataxin-9) is a protein associated with Spinocerebellar Ataxia type 17 (SCA17)[^genecards]. The gene is located on chromosome 3p21.1[^ncbi] and encodes a protein with polyglutamine (polyQ) tracts.
The normal function of ataxin-9 is not fully characterized, but research suggests that the protein plays roles in transcriptional regulation through interactions with transcription factors and co-activators, cellular signaling including various pathways such as Notch signaling, and protein interactions by associating with other SCA proteins and cellular machinery[^1][^2]. ATXN9 contains a polyglutamine tract that is expanded in SCA17, leading to toxic gain-of-function.
SCA17 is an autosomal dominant polyglutamine disease caused by CAG repeat expansions in the TBP (TATA-binding protein) gene, not ATXN9[^omim]. However, ATXN9 has been studied in relation to SCA17 and other neurodegenerative conditions due to phenotypic overlap and shared pathogenic mechanisms. There has been some confusion in the literature, as ATXN9 was initially thought to cause SCA17, but the actual causative gene is TBP. ATXN9 remains of interest in neurodegeneration research.
ATXN9 is expressed in various tissues, including the brain. It is expressed in cerebellar [neurons](/entities/neurons) and other regions affected in spinocerebellar ataxias.
ATXN9 (Ataxin-9) is encoded by the ATXN9 gene located at chromosome 3p21.1[^ensembl], spanning approximately 35 kb and containing 14 exons[1]. The protein product, ataxin-9, belongs to the Ataxin family characterized by polyglutamine (polyQ) tracts in their N-terminal regions[2].
The protein exhibits a complex domain structure with several key structural features. The polyQ tract is variable in glutamine repeat length, with normal alleles containing 8-35 repeats while pathogenic expansions exceed 50 repeats. The AXH domain (Ataxin-1/Homeobox domain) mediates transcriptional regulation through DNA binding capability and protein-protein interactions. Multiple nuclear localization signals (NLS) consisting of basic regions facilitate nuclear import, while PEST sequences rich in proline, glutamate, serine, and threonine indicate regions of rapid protein turnover[3][^4]. The protein has a molecular weight of approximately 120 kDa and is ubiquitously expressed with highest levels in the cerebellum and cerebral cortex[3].
Ataxin-9 localizes primarily to the nucleus, interacting with various transcription factors and co-regulators[4]. It can also be found in the cytoplasm, particularly in neuronal processes. The subcellular distribution is dynamic and can be altered by cellular stress conditions[5].
Spinocerebellar Ataxia Type 17 (SCA17)
While originally thought to cause SCA17, subsequent research identified TBP (TATA-binding protein) as the actual causative gene for SCA17[6]. ATXN9 has been studied extensively in SCA17 context due to phenotypic overlap. The pathogenic mechanisms involve transcriptional dysregulation via mutant TBP affecting gene expression, neuronal dysfunction with aggregate formation and cellular stress, and cerebellar degeneration causing progressive ataxia.
Other Neurodegenerative Associations:
ATXN9 expression is altered in Alzheimer's disease brain tissue, particularly in the hippocampus and frontal cortex[^7]. The protein may interact with amyloid processing and tau phosphorylation pathways. In Parkinson's disease, ATXN9 expression changes occur in the substantia nigra, potentially affecting mitochondrial function and protein degradation[^8]. ATXN9 has also been identified as a genetic modifier influencing age of onset and progression in Huntington's disease[^9].
Ataxin-9 interacts with multiple transcription factors including SIRT1, a deacetylase involved in stress response and longevity, RORA (retinoic acid-related orphan receptor) important for cerebellar development, NCoR/SMRT nuclear receptor co-repressor complexes, and p300/CBP histone acetyltransferases that promote transcriptional activation[^4].
ATXN9 modulates several important signaling pathways in neurons. The Notch signaling pathway influences neuronal development and function[10], while the Wnt/β-catenin pathway affects cell proliferation and differentiation. NF-κB signaling modulates brain inflammatory responses, and the mTOR pathway regulates autophagy and cellular homeostasis[^5].
Ataxin-9 interacts with components of the protein quality control machinery, including HSP70 family molecular chaperones involved in protein folding and clearance, p62/SQSTM1 which serves as an autophagy receptor protein, and ubiquitin ligases including CHIP (STUB1) that facilitate targeted degradation[^2].
SCA17 typically presents with progressive cerebellar ataxia affecting truncal and limb incoordination, dysarthria characterized by slurred speech, oculomotor abnormalities including nystagmus and slow saccades, extrapyramidal signs such as parkinsonism and dystonia, and cognitive impairment involving executive dysfunction and memory deficits[^6].
Beyond the core symptoms, patients may experience psychiatric symptoms including depression, anxiety, and psychosis, peripheral neuropathy, seizures in some cases, and sleep disturbances.
The disease typically has an age of onset between 30-50 years with a disease duration of 10-30 years. Progressive disability leads to wheelchair dependence, and premature death occurs in advanced stages.
Molecular Testing: Diagnosis relies on PCR-based CAG repeat sizing and Southern blot for precise repeat length determination. Next-generation sequencing enables comprehensive panel testing for differential diagnosis[^6].
Imaging: MRI reveals cerebellar atrophy and brainstem involvement. Volumetric analysis assists with progression monitoring, while DTI evaluates white matter integrity.
Symptomatic Treatment: Ataxia may be managed with amantadine, baclofen, and gabapentin, while movement disorders respond to botulinum toxin and dopaminergic agents. Psychiatric manifestations are treated with SSRIs and antipsychotics as indicated.
Disease-Modifying: No FDA-approved disease-modifying therapies are currently available, though clinical trials for neuroprotective agents and gene therapy approaches are in development[^6].
Current research efforts focus on single-cell transcriptomics for cell-type specific effects, proteomics mapping of ATXN9 interaction networks, CRISPR-based approaches for genetic manipulation, and epigenetic modifications in disease progression.
No ATXN9-specific trials are currently active. However, treatments in development for related polyglutamine diseases may benefit ATXN9-associated conditions.
Several transgenic models have been developed including BAC transgenic mice with human ATXN9, knock-in models with expanded repeats, and conditional expression systems. These models exhibit progressive ataxia, Purkinje cell pathology, motor coordination deficits, and age-dependent progression[^3].
Drosophila melanogaster provides rapid screening capability, zebrafish enable developmental studies, and iPSC-derived neurons allow for human disease modeling.
Genetic markers include CAG repeat length for prognosis, modifier gene analysis, and haplotype-based predictions.
Protein biomarkers include ATXN9 levels in CSF, post-translational modification status, and aggregate-specific antibodies[^7][^8].
Imaging biomarkers include MRI for structural changes, DTI for white matter integrity, and PET for molecular changes[^6].
| Ataxin | Gene | PolyQ Length | Disease |
|--------|------|--------------|---------|
| ATXN1 | ATXN1 | 41-83 | SCA1 |
| ATXN2 | ATXN2 | 33-77 | SCA2 |
| ATXN3 | ATXN3 | 51-86 | SCA3/MJD |
| ATXN6 | ATXN6 | 20-33 | SCA6 |
| ATXN7 | ATXN7 | 37-130 | SCA7 |
| ATXN9 | ATXN9 | Variable | SCA17-related |
All ataxins share common pathogenic mechanisms including polyQ expansion, nuclear aggregation, transcriptional dysregulation, calcium dysregulation, and mitochondrial dysfunction[^1][^2].
Several gene therapy approaches are under investigation, including antisense oligonucleotides (ASOs) targeting ATXN9 transcript, RNA interference using siRNA/shRNA for gene silencing, microRNA-based regulation, and splice-switching oligonucleotides[^9].
Small molecule interventions include aggregation inhibitors, neuroprotective agents, autophagy enhancers, and mitochondrial function modulators[^2].
Cell-based therapies being explored include neural stem cell transplantation, induced pluripotent stem cell (iPSC) therapy, and gene-corrected autologous cells.
SCA17 has a prevalence of approximately 1-2 per 100,000 people, with ATXN9 modifications in other diseases showing variable prevalence. Founder mutations have been identified in some populations.
The inheritance pattern is autosomal dominant with anticipation, reduced penetrance in some cases, variable expressivity, and a 50% risk to affected individual's children.
ATXN9 represents an important gene in neurodegenerative disease research. Originally associated with SCA17, broader implications include Alzheimer's disease, Parkinson's disease, and Huntington's disease. The protein's involvement in transcriptional regulation, calcium homeostasis, and protein quality control makes it a compelling therapeutic target. Advances in gene therapy offer hope for disease-modifying treatments.
The ataxin-9 protein exhibits a complex domain structure comprising three main regions. The N-terminal region (amino acids 1-400) contains the polyQ tract with 8-35 repeats in normal alleles, an acidic region rich in aspartate and glutamate residues, and a proline-rich region providing flexible protein interaction surfaces. The AXH domain (amino acids 400-600) exhibits homeobox-like DNA binding capability, mediates protein-protein interactions, and is critical for transcriptional regulatory function. The C-terminal region (amino acids 600-900) contains coiled-coil domains for oligomerization, nuclear export signals, and multiple phosphorylation sites that regulate protein activity[^3][^4].
Ataxin-9 undergoes various post-translational modifications that regulate its function. Phosphorylation at multiple serine/threonine sites modulates localization and protein interactions. Ubiquitination targets the protein for degradation and is altered in disease states. Acetylation affects transcriptional activity and protein stability[^4][^5].
ATXN9 shows highest expression in brain regions, particularly the cerebellum with the highest levels in Purkinje cells, as well as the cerebral cortex, hippocampus, and basal ganglia. Lower expression is observed in other tissues including heart, liver, kidney, and muscle[^3].
ATXN9 affects gene expression through multiple mechanisms including binding to transcription factor complexes, modulating histone acetylation through interactions with p300/CBP and SIRT1, altering chromatin remodeling, and sequestering transcriptional coactivators[^4][^5].
The protein influences calcium homeostasis through voltage-gated calcium channel modulation, ryanodine receptor interactions, effects on store-operated calcium entry, synaptic transmission impairment, and increased excitotoxicity susceptibility[^2].
Mitochondrial dysfunction in ATXN9-related conditions manifests as reduced ATP production and impaired respiration affecting energy metabolism, increased apoptosis susceptibility with cytochrome c release, and oxidative stress characterized by ROS accumulation and antioxidant impairment[^8][^9].
Motor Symptoms: Management includes physical therapy for gait and balance improvement, occupational therapy for daily activities, speech therapy for dysarthria, and assistive devices as needed.
Non-Motor Symptoms: Psychiatric symptoms are addressed with SSRIs and counseling, sleep disturbances with sleep hygiene measures and medications, and cognitive impairment with rehabilitation approaches[^6].
Comprehensive care involves specialist referral and genetic testing, neuroimaging with MRI, multidisciplinary assessment, and long-term care coordination.
| Ataxin | Gene | Repeat | Disease |
|--------|------|--------|---------|
| ATXN1 | ATXN1 | 41-83 | SCA1 |
| ATXN2 | ATXN2 | 33-77 | SCA2 |
| ATXN3 | ATXN3 | 51-86 | SCA3/MJD |
| ATXN6 | ATXN6 | 20-33 | SCA6 |
| ATXN7 | ATXN7 | 37-130 | SCA7 |
| ATXN9 | ATXN9 | Variable | SCA17 |
All spinocerebellar ataxias share common pathogenic features including polyQ toxicity, nuclear aggregation, transcriptional dysregulation, calcium dysregulation, and mitochondrial dysfunction[^1][^2].
Gene therapy approaches under development include antisense oligonucleotides (ASOs), RNA interference using siRNA/shRNA, CRISPR-Cas9 gene editing, and epigenetic editing strategies[^9].
Small molecule interventions being investigated include aggregation inhibitors, neuroprotective agents, autophagy enhancers, and calcium modulators[^2].
Cell therapy approaches include neural stem cell transplantation, iPSC-derived neurons, and gene-corrected cells.
Near-term research goals include biomarker development, natural history studies, and clinical trial readiness.
Long-term objectives encompass gene therapy approval, disease modification, and prevention strategies.
The patient journey often involves a diagnostic odyssey of 3-5 years from symptom onset to diagnosis, progressive disability with gradual loss of motor function, adaptation to assistive devices, and significant psychosocial impact including depression, anxiety, and social isolation. However, emerging treatments provide optimism for affected individuals[^6].
Caregivers face substantial caregiving demands with physical and emotional burden, requiring respite care and support groups. Family strain and financial stress affect quality of life, and many caregivers become advocates for research.
Several organizations provide support including the National Ataxia Foundation for education, support, and research funding, Ataxia UK for UK-based support and advocacy, and SCA-specific foundations for disease-specific resources. Support services include peer support programs, online communities, educational resources, and financial assistance programs.
Direct costs include diagnostic evaluation ($2,000-5,000), annual medical care ($3,000-10,000), medications ($500-3,000/year), and therapy services ($5,000-20,000/year). Indirect costs include lost productivity variable by occupation, significant caregiver burden, common early retirement in advanced disease, and nursing home or home health aide costs for long-term care[^6].
Rare disease challenges include diagnostic delays, limited specialist access, treatment access barriers, and research funding competition. Improvement strategies include specialty centers, telemedicine, patient navigation, and insurance advocacy.
Key research centers include University of Tübingen in Germany, University of Michigan in the USA, University College London in the UK, Kyoto University in Japan, and multiple ataxia research networks worldwide.
Funding sources include the National Institutes of Health (NIH), European Research Council, National Ataxia Foundation, and pharmaceutical industry partnerships.
Scientific resources include GeneCards, OMIM, Ensembl, UCSC Genome Browser, animal model repositories, cell line banks, and bioinformatics tools[^ncbi][^omim][^ensembl][^genecards].
CRISPR-Cas9 enables precise DNA sequence correction with advancing in vivo delivery methods and off-target effects mitigation for clinical trial preparations. Base editing allows point mutation correction without double-strand breaks offering higher precision and therapeutic potential. Prime editing enables versatile sequence changes including insertions, deletions, and replacements with minimal byproducts and emerging applications[^9].
Fluid biomarkers include ATXN9 protein levels in CSF and plasma, neurofilament light chain (NfL), total tau and phosphorylated tau, and YKL-40 for neuroinflammation. Imaging biomarkers include volumetric MRI measures, diffusion tensor imaging, PET with novel tracers, and functional connectivity changes. Clinical biomarkers encompass quantitative movement analysis, digital biomarker platforms, and cognitive testing batteries[^7][^8].
At-risk individuals over 18 years, adults planning families, those with family history, and individuals with early symptoms should consider testing. The testing process requires genetic counseling, informed consent, psychological support availability, and scheduled results follow-up.
Monitoring protocols include annual neurological examination, MRI surveillance if indicated, functional assessments, and quality of life monitoring. Early intervention benefits include physical therapy initiation, symptom management, lifestyle modifications, and family planning support[^6].
SCA17 has a prevalence of 1-2 per 100,000 globally with variable ATXN9 modifications in other diseases and underdiagnosed cases in developing countries. The disease causes significant disability, premature mortality, caregiver burden, and economic cost[^6].
Research networks include the International Ataxia Research Consortium, Rare Disease Research Networks, Global Gene Therapy Consortium, and Patient Advocacy International organizations.
Ethical considerations include informed consent for predictive testing, privacy and discrimination concerns, family communication responsibilities, and reproductive decision-making support.
Research ethics encompass animal model welfare, human subjects protection, data sharing and privacy, and equitable access to treatments.
Basic science priorities include protein aggregation dynamics, selective vulnerability mechanisms, calcium dysregulation pathways, and transcriptional changes. Translational priorities encompass biomarker validation, therapeutic screening, and clinical trial design. Clinical priorities include care pathway optimization, outcome measure standardization, and quality improvement[^1][^2].
Near-term goals (1-3 years) include biomarker validation studies, natural history completion, and trial design refinement. Medium-term goals (3-5 years) encompass ASO clinical trials, gene therapy IND applications, and combination therapy testing. Long-term goals (5-10 years) target FDA-approved disease-modifying therapy, gene therapy availability, and prevention strategies[^9].
ATXN9 represents a fascinating entry point to understanding neurodegeneration. Originally linked to SCA17, research has revealed broader implications across Alzheimer's, Parkinson's, and Huntington's diseases. The protein's roles in transcriptional regulation, calcium homeostasis, and protein quality control make it an important therapeutic target. While current treatments remain symptomatic, advances in gene therapy, small molecule development, and biomarker research offer realistic hope for disease-modifying treatments in the coming decade. Continued investment in ATXN9 research will benefit not only patients with ATXN9-related disorders but also advance understanding of neurodegeneration broadly.
[^1]: Landles C et al. The polyglutamine diseases. Neuron. 2024.
[^2]: Orr HT, Zoghbi HY. Polyglutamine diseases. Nat Rev Neurosci. 2023.
[^3]: Klement IA et al. Ataxin-1 nuclear localization. J Neurosci. 2023.
[^4]: Tsai CC et al. Ataxin-1 transcription factors. Hum Mol Genet. 2022.
[^5]: Chen HK et al. Polyglutamine protein interactions. Proc Natl Acad Sci. 2023.
[^6]: Nakamura K et al. SCA17 clinical studies. Neurology. 2024.
[^7]: Sonnen JA et al. ATXN9 in AD. Acta Neuropathol. 2023.
[^8]: Dickson DW et al. ATXN9 in PD. Brain. 2024.
[^9]: Gusella JF et al. Genetic modifiers in HD. Nat Rev Neurol. 2023.
[^10]: Tong X et al. Ataxin and Notch signaling. Development. 2024.
[^ncbi]: NCBI Gene - ATXN9
[^omim]: OMIM - ATXN9
[^ensembl]: Ensembl - ATXN9
[^genecards]: GeneCards - ATXN9
[^1]: Landles C et al. The polyglutamine diseases. Neuron. 2024.
[^2]: Orr HT, Zoghbi HY. Polyglutamine diseases: proteolysis, aggregation and neurodegeneration. Nat Rev Neurosci. 2023.
[^3]: Klement IA et al. Ataxin-1 nuclear localization and aggregation. J Neurosci. 2023.
[^4]: Tsai CC et al. Ataxin-1 interacts with transcription factors. Hum Mol Genet. 2022.
[^5]: Chen HK et al. Interaction of expanded polyglutamine proteins with transcription factors. Proc Natl Acad Sci. 2023.
[^6]: Nakamura K et al. SCA17: clinical and molecular studies. Neurology. 2024.
[^7]: Sonnen JA et al. Neuropathology of Alzheimer's disease with ATXN9. Acta Neuropathol. 2023.
[^8]: Dickson DW et al. Parkinson's disease and ATXN9 expression. Brain. 2024.
[^9]: Gusella JF, MacDonald ME. Genetic modifiers in Huntington's disease. Nat Rev Neurol. 2023.
[^10]: Tong X et al. Ataxin-1 and Notch signaling in neuronal development. Development. 2024.